The market has been rattled in recent weeks, and the numbers speak for themselves. The ASX 200 is down sharply from its highs, Wall Street has tumbled into correction territory, and investor sentiment has taken a hit.
But while the headlines scream panic, experienced investors know these are often the moments when opportunity knocks the loudest. Quality companies get marked down alongside everything else, not because their fundamentals have changed — but because fear takes over.
So, if you're looking to take advantage of the recent market selloff, here are three ASX shares that analysts believe are worth a closer look right now. They are as follows:
Image source: Getty Images
Macquarie Group Ltd (ASX: MQG)
Often referred to as Australia's global investment bank, Macquarie has built a reputation for navigating tough environments and coming out stronger. With diversified earnings across infrastructure, asset management, green energy, and banking, it is positioned to benefit from multiple long-term themes.
The market pullback has dragged its share price down, but the business remains in great shape. Macquarie is also known for rewarding shareholders through dividends and capital returns. If you're looking for a high-quality financial with global reach, this could be the time to act.
Morgan Stanley has an overweight rating and $224.00 price target on its shares.
Lovisa Holdings Ltd (ASX: LOV)
Down massively from its highs, Lovisa has arguably become one of the standout value plays in the retail sector. The fast fashion jewellery retailer has been expanding globally at pace, with huge opportunities in North America and Europe.
While the market has punished retail names during the selloff, Lovisa's growth engine remains in full swing. The recent pullback could present a rare chance to pick up this high-growth stock at a discount — and patient investors may be rewarded as momentum returns.
Bell Potter is bullish and has a buy rating and $30.00 price target on its shares.
CSL Ltd (ASX: CSL)
One of the ASX's most respected healthcare companies, CSL has taken a hit during the recent market selloff. But fundamentally, the core business hasn't skipped a beat. Its plasma collection business is back to full strength and is forecast to underpin double-digit earnings growth in the coming years.
So, if you're looking for a blue-chip with resilience and long-term tailwinds, CSL could be a great addition while it's trading well below its highs.
Goldman Sachs rates it as a buy with a $318.40 price target.
